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ABSTRACT
Introduction: Human primary immunodeficiency diseases (PIDs) include a broad spectrum of more
than 350 disorders, involving different branches of the immune system and classified as ‘rare diseases.’
Predominantly antibody deficiencies (PADs) represent more than half of the PIDs diagnosed in Europe
and are often diagnosed in the adulthood.
Areas covered: Although PAD could first present with autoimmune or neoplastic features, respiratory
infections are frequent and respiratory disease represents a relevant cause of morbidity and mortality.
Pulmonary complications may be classified as infection-related (acute and chronic), immune-mediated,
and neoplastic.
Expert opinion: At present, no consensus guidelines are available on how to monitor and manage lung
complications in PAD patients. In this review, we will discuss the available diagnostic, prognostic and
therapeutic instruments and we will suggest an appropriate and evidence-based approach to lung
diseases in primary antibody deficiencies. We will also highlight the possible role of promising new
tools and strategies in the management of pulmonary complications. However, future studies are
needed to reduce of diagnostic delay of PAD and to better understand lung diseases mechanisms,
with the final aim to ameliorate therapeutic options that will have a strong impact on Quality of Life
and long-term prognosis of PAD patients.
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1. Introduction
Human primary immunodeficiency diseases (PIDs) include
a broad spectrum of disorders (more than 350 according to
the International Union of Immunological Societies – IUIS –
classification), involving different branches of the immune
system [1]. Most of them are defined by a well-known under-
lying genetic defect [1,2]. PIDs are known as ‘rare diseases,’ but
their global incidence might be much more relevant than
what generally thought [3]. It has been estimated that some-
thing around 6 million people worldwide might be affected by
a PID, no more than 1% of which having been definitely
diagnosed [4]. The immunologic defect may be broad or
extremely selective/specific, implying a huge heterogeneity
in infectious manifestations, both in terms of severity and
range of involved pathogens [1]. Moreover, infections might
not be the main features of certain PIDs (e.g. hereditary
angioedema, IPEX or auto-inflammatory disorders). Indeed,
the first clinical presentation of some PIDs may be an auto-
immune disease or cancer [5,6]. This variability gives a reason
for the high degree of underdiagnosis or diagnostic delay.
Despite representing a small number of the IUIS-recognized
diseases, predominantly antibody deficiencies (PADs) represent
more than a half of the PIDs diagnosed in Europe, according to
the ESID registry, and the percentage increases if we consider
adult patients [7]. Either B cell intrinsic or B cell extrinsic defects
may lead to the impairment in antibody production, but the
genetic and mechanistic etiologies are still unknown for the
majority of patients. The most prevalent symptomatic PAD,
indeed, Common Variable Immunodeficiency (CVID), is charac-
terized by a variable phenotype whose genetic basis is still
under investigation [8].
Compared to cellular or combined immunodeficiencies,
defects of the humoral immune response tend to have
a better long-term prognosis and are often diagnosed in the
adulthood, with a peak around the third decade of life [9].
A recent paper based on ESID registry reported a median age
at diagnosis of 31 and a mean of 31.4 years for CVID [10].
Respiratory disease is a relevant cause of morbidity and mor-
tality in PAD patients [11]. Pulmonary complications may be
classified as infection-related (acute and chronic), immune-
mediated and neoplastic [12]. Respiratory tract infections
(RTI) need an immediate and appropriate diagnostic approach.
Due to recurrence, underlying immune defects, diagnostic
delay, and not always appropriate management, infections
may lead to long-term consequences on airways architecture
and function, inducing bronchiectasis, COPD and poor asthma
control. Immune-mediated complications encompass a range
of interstitial lung diseases (ILDs), that might all be part of
a specific entity called GLILD (Granulomatous-Lymphocytic
Interstitial Lung Disease). Finally, malignancies are a major
cause of morbidity and mortality in PAD and may involve
the respiratory tract [5,6,11,13].
No worldwide accepted or European consensus guidelines
are currently available on how to monitor and manage lung
complications in PID patients. A recent survey, indeed, showed
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a great heterogeneity in the frequency of clinical, functional
and radiologic evaluation of patients’ lung health across
Europe [14]. Herein we will discuss the available diagnostic,
prognostic and therapeutic instruments and we will suggest
an appropriate and evidence-based approach to lung diseases
in primary antibody deficiencies. We will focus on those dis-
eases listed between the ‘predominantly antibody deficiency’
in the IUIS classification, particularly referring to those in
which IgG replacement represents the standard of therapy [1].
2. Primary antibody deficiencies
The spectrum of Primary Antibody Deficiencies ranges from
conditions with Mendelian inheritance, as X-linked (XLA) or
autosomal recessive Agammaglobulinemia, to diseases with
predominant polygenic inheritance, such as Common
Variable Immunodeficiency (CVID) [9]. Mature B cells may
thus be absent, as in XLA, or may present an almost normal
development, being selectively impaired only the antibody
response to polysaccaridic antigens, as in Specific Antibody
Deficiencies (SpAD). Inadequate response to micro-organisms
goes together with a poor response to vaccination (e.g. 23-
valent anti-pneumococcal vaccine), that is indeed included
between the diagnostic criteria for CVID [9].
Due to the lack of protective antibodies, the respiratory
tract is the major target for acute infections, requiring
immunoglobulin replacement therapy and frequent courses
of antibiotics [15,16]. Recent studies underline that IgG
replacement therapy enhances survival and reduces risk of
pneumonia and other invasive infections [17], but substitu-
tive therapy, even at high dose, cannot block the develop-
ment of chronic infection-related pulmonary diseases
[18,19].
Apart from the infection-related symptoms, PAD may be
characterized by an increased incidence of allergic and auto-
immune diseases, polyclonal lymphoproliferation and cancer,
due to an underlying immune dysregulation usually accompa-
nying the immune defect [20–22].
3. Pulmonary complications of PADs and their
management
3.1. Infections and infection-related diseases
PAD-associated acute infections (e.g. pneumonia) and
chronic infection-related lung diseases (bronchiectasis,
COPD) have been accurately described in several reviews
and retrospective studies [12,23–25]. The defect in antibody-
mediated response explains the susceptibility to bacterial
infections and their recurrence. The impaired response also
influences the time to complete recovery despite appropri-
ate treatment, the rate of colonization in the presence of
bronchiectasis and the degree of resistance following the
repeated use of antibiotics [25]. Selective IgA deficiency
(sIgAD) may be asymptomatic or mildly symptomatic in
terms of infections, that mainly involve the respiratory
tract [26]. The co-existence of an IgG subclass deficiency
may significantly worsen the infectious phenotype [27].
IgG deficiency is characterized by recurrent sinopulmonary
infections, with rates of sinusitis and pneumonia similar to
CVID; CVID patients, however, present a significantly higher
prevalence of bronchiectasis and of non-infectious compli-
cations [28]. Moreover, diseases as congenital agammaglo-
bulinemia and hyper-IgM syndromes (HIgM) (when due to
a defective CD40:CD40 ligand interaction), may present
a deeper immune defect if compared to other PADs, leading
to a more severe infectious phenotype with increased sus-
ceptibility, respectively, to certain viral infections or to
opportunistic infections like Pneumocystis Jirovecii [29,30].
More in general, it has been suggested that in PADs the
impairment in immune response might be broader than
what commonly thought, involving multiple non-B cell
immunological defects, such as T-cell, MBL, TLR, AMP defi-
ciency, and/or impaired neutrophil function [31]. Recent
studies, indeed, highlighted the increased frequency of
viral infections and viral-plus-bacterial co-infections in PAD
patients, particularly during symptomatic respiratory exacer-
bations [25,32]. This might explain why, in agammaglobuli-
nemic as in some CVID patients, chronic lung disease
progression still occurs despite maintaining an appropriate
IgG trough level, with a rate of decline in lung function that
is approximately twofold in CVID patients compared to the
rate of healthy non-smoking adults [24,33,34].
Article highlights
● Internationally recognized evidence-based guidelines need to be
designed, in order to standardize the approach to diagnosis, mon-
itoring, and treatment of lung diseases in PAD. This will go through
technical improvements and new acquisitions in terms of pathogenic
mechanisms and will reduce the diagnostic delay of lung complica-
tions, improving patients’ QoL and survival.
● IgG replacement therapy enhances survival and reduces severe and
invasive infections. However, patients might still develop chronic
infection-related lung disease (CLD). Adjunct therapies as
Azithromycin prophylaxis, pulmonary rehabilitation, and new IgA
and IgM enriched Ig preparations that will soon be available need
to be included in standardized guidelines, in order to prevent the
progression of CLD.
● HRCT scan still represents the gold standard for lung imaging in
PADs. Recent evidence supports the possible role of lung magnetic
resonance imaging (MRI) in diagnosing and monitoring lung disease
in PAD patients. Without exposure to ionizing radiation, recently
developed chest MRI techniques might offer both structural and
functional information in a single examination. MRI is thus destined
to become a routinely used lung imaging approach for PAD patients.
● GLILD, whose diagnosis is currently based on a multi-step process
culminating in an invasive open-lung or VATS biopsy, still represents
a great challenge. In the next future, the diagnostic process will hope-
fully move to a more clinical-radiologic-plus-MDT-discussion-based
approach, with an increasing importance of BAL. Cryo-biopsy will likely
become the first-line approach when a lung tissue biopsy is needed.
● In terms of treatment, we are looking for interesting correlations
between GLILD behavior and possible predisposing factors, under-
lying genetic defects, concomitant conditions, peripheral blood or
BALF lymphocytes distribution, histochemical characterization of tis-
sue samples. These correlations will emerge from ongoing observa-
tional studies and from case series, allowing clinicians to consider
more tailored treatment strategies either on the basis of patients’
classification in subgroups, or starting from the immunologic
mechanisms highlighted in each single patient.
● Starting from a better understanding of mechanisms and correlations,
relatively large multicenter-controlled trial with existing drugs will be
designed, hopefully leading to PAD-specific evidence-based treat-
ment guidelines for ILDs.
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3.1.1. Acute infections
To promptly manage acute pulmonary infections in PAD
patients, early imaging (computed tomography [CT] scan)
and specific microbiologic sampling represent the optimal
approach. The latter may require non-invasive tests (e.g spu-
tum culture), but invasive procedures (e.g. bronchoscopy to
reveal bacterial grown in bronchoalveolar lavage fluid, lung
biopsies in case of solid/cavitary lesions) are often necessary to
obtain a representative sample. Once the microbiologic diag-
nosis is established, an antimicrobial susceptibility test will
determine the drug of choice. Sometimes advanced diagnostic
testing including immunohistochemistry and quantitative
molecular assays may be performed as additional components
in the diagnostic algorithm [35,36].
The importance of early antimicrobial therapy cannot be
overemphasized, accordingly broad-spectrum antimicrobial
therapy must be started as soon as possible, considering
patients’ epidemiologic history and any prior microbiologic
data or previous courses of antimicrobial agents. A list of the
most involved pathogens is reported in Table 1. Once the
microbiologic diagnosis is made, empiric therapy can be mod-
ified accordingly. The optimal duration of antimicrobial treat-
ment of PAD patients has not been defined, even if is
generally accepted the need for longer courses if compared
to immunocompetent individuals. Experienced clinicians often
prescribe courses of antimicrobials that are at least two times
longer than standard recommendations.
Furthermore, to provide adequate Ig replacement therapy
is essential in this context. As no specific IgG trough concen-
tration has been defined, target IgG trough level should be the
one able to keep the patient infection-free [24]. Therefore,
transiently, higher doses of Ig (600–800 mg/kg/month) may
help to clear acute bacterial infections and possibly to prevent
the evolution towards chronic lung disease [45,46].
3.1.2. Chronic infection-related airways diseases
The cumulative incidence of chronic lung diseases has been
decribed to reach 80% after a 17-year follow-up in a cohort
of XLA patients [47] while in CVID, the incidence of bronch-
iectasis has been shown to increase over time for almost all
age groups, leading to an increased risk of death [24,25,48].
More generally, a recently published study showed radiolo-
gical evidence of bronchial pathology (bronchiectasis in
61%, bronchial wall thickening in 44% and mucus plugging
in 29%) in 80% of chest HRCT scan of a multicenter cohort
of CVID patients [49]. Chronic infection-related lung damage
(e.g. bronchiectasis) has not been reported as a significant
feature of sIgAD [26,50]. The co-existence of an IgG subclass
deficiency has been shown to be crucial in terms of chroni-
city and severity of lung disease [27]. The high incidence of
chronic lung diseases is a direct consequence of diagnostic
delay, severity of the infectious respiratory phenotype, and
difficulty to define appropriate treatment strategies. The
recurrence of acute infections over these underlying chronic
lung conditions has been proposed to be defined as respira-
tory exacerbations of PAD patients, using the definition
already validated for COPD [25]. Respiratory exacerbations
in PAD are mainly caused by encapsulated bacteria. Despite
an appropriate IgG replacement therapy, indeed, low IgM
and particularly low IgA serum levels have been found to be
risk factors for S. pneumoniae and H. influenzae airways
colonization [51]. Chronic lung disease (CLD) is a relevant
cause of mortality in PAD patients. In a cohort of XLA
patients, after 25 years of follow-up, 38% of deaths were
due to CLD. In an Italian cohort of CVID patient, death for
respiratory failure due to chronic lung disease accounted for
30.4% of all causes of death [6,47].
3.1.2.1. Bronchiectasis. The most prevalent chronic infection-
related lung disease diagnosed in PADs is bronchiectasis [10,34].
Other chronic pulmonary complications affecting airways include
chronic obstructive pulmonary disease (COPD) and asthma
[31,52]. Bronchiectasis present as atypical bronchial and bronch-
iolar dilatations, resulting from a ‘vicious cycle,’ in which repeated
episodes of infection and inflammation lead to the destruction of
the airways and lung parenchyma, with a consequent decline in
lung function [31,53–55] (Figure 1). A recent retrospective study
on adult patients with primary antibody deficiencies reported 47%
suffering from bronchiectasis; history of LRTI was the only factor
directly associated with the development of bronchiectasis
[19,56]. However, it has also been demonstrated that, once the
remodeling process is ongoing, airway inflammation gets worse
even in the absence of bacterial infection. This is related to neu-
trophil accumulation through an increase in pro-inflammatory
cytokines expression and adhesion molecule production. Over
time, airway inflammation leads to hyper-reactivity, further lung
remodeling, and development of new bronchiectasis [57,58]. In
PAD patients, defects and dysregulation of the immune system
further enhance this vicious cycle [31].
3.1.2.2 Management. The management of bronchiectasis
has been extensively studied in cystic fibrosis (CF) patients.
On the contrary, there is no standardized treatment for adult
non-cystic fibrosis bronchiectasis (NCFB), including those
related to PIDs, and therapeutic strategies tend to be simply
extrapolated from CF clinical trials [59]. Several clinical trials
Table 1. Infectious pathogens reported in respiratory tract infections (RTI) in PADs.
Type of pathogen Isolated pathogen Reference
Bacteria Frequent: Haemophilus influenzae type B, Streptococcus pneumoniae, Pseudomonas spp, Staphylococcus spp.
(incl. Methicillin resistant), Mycoplasma spp, Neisseria meningitidis, Moraxella spp.
[25,31,32,37–40,92]
Rare: Klebsiella spp, Bordetella pertussis, Chlamydia trachomatis, Ureaplasma urealyticum, Fusobacteriumspp,
Serratia spp, Stenotrophomonas maltophilia, Enterobacterspp, Proteus spp, Achromobacter xylosoxidans,
Citrobacter spp.
Virus Rhinovirus, Adenovirus, Coronavirus, Influenza A, Influenza B, enterovirus, RSV, hMPV [31,41,42]
Opportunistic pathogens
(rare, reported in XLA
and HIGM)
Mycobacterium hominis, Mycobacterium avium, Pneumocystis Jirovecii [29,31,40,43,44,92]
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have proven that macrolide antibiotics are effective to suc-
cessfully manage cystic fibrosis (CF), non-CF associated
bronchiectasis (NCFB), COPD, and asthma [60–64] all condi-
tions with a lower rate of respiratory exacerbations in compar-
ison to severe PAD. Macrolides, especially azithromycin, have
antimicrobial, immunomodulatory and anti-inflammatory
properties, and prevent the development of the biofilm pro-
duced by bacteria, acting on the vicious circle infection-
inflammation that leads to airway hyper-reactivity and remo-
deling [57]. Differently from these respiratory diseases, no
guidelines to manage respiratory diseases in PAD patients
are available. Despite lacking specific evidence, physiotherapy
programs and antibiotic prophylaxis have been routinely used
in PAD patients with bronchiectasis [65–67]. Only few reviews
have been written on the use of antimicrobial prophylaxis in
PAD. According to these papers, the efficacy of antimicrobial
prophylaxis in PADs patients remains uncertain and the risk of
bacterial resistance makes this practice poorly widespread.
However, PAD patients might take advantage of antibiotics
prophylaxis [8]. Up to now the use of antibiotic prophylaxis in
CVID has been heterogeneous and mainly based on single-
institution-specific experience [68]. There has been no con-
sensus on which antibiotic agent to use, at what dose (half of
a therapeutic dose, full doses) and on how to schedule the
prophylactic regimen (intermittent single agent, rotational
antibiotics, periodically changing antibiotics monthly to
every 6 months). Moreover, the available reports were neither
based on randomized clinical trial, nor associated with con-
trolled measurements of patients safety and quality health
outcomes [69]. Recently, new data on antibiotic prophylaxis
in PAD patients became available from a 36-month, Phase II,
randomized, double-blind, placebo-controlled, multi-center
clinical trial on long-term prophylactic treatment with azithro-
mycin in adult PAD patients [70]. In that trial, 89 PAD patients
with bronchiectasis and/or COPD were enrolled. Patients
received for 24 months either azithromycin, 250 mg once
daily for three consecutive days per week, or an identical-
appearing placebo. The study showed that long-term oral
azithromycin prophylaxis in patients affected by primary anti-
body deficiencies and chronic infection-related pulmonary
diseases significantly reduced the episodes of respiratory
exacerbations per patient-year. Moreover, in the group of
patients receiving azithromycin, the number of additional
courses of antibiotics for treating respiratory exacerbations
was lower than in the placebo group, as well as the number
of hospitalizations. In addition, after starting azithromycin,
decreased counts of absolute number of WBC and neutrophils
were observed. The administration of azithromycin was pro-
ven to be safe as no serious adverse events or drug-related
cardiovascular mortality were reported. It had been previously
demonstrated that daily intake of low dose of azithromycin
resulted in development of azithromycin-resistant pathogens,
whereas the same dose given 3 times a week did not increase
bacterial resistance [71]. During the study time, indeed, an
increased rate of macrolide-resistant organisms was not
observed in the azithromycin compared to the placebo
group [70]. These results were comparable with those already
provided by other similar randomized studies done in COPD,
in CF patients and in non-CF patients with bronchiectasis,
although a lower azithromycin dosage has been used [60–
64]. The efficacy of a low-dose macrolide prophylaxis on PAD
respiratory exacerbations could be related both to antimicro-
bial and anti-inflammatory action of the macrolides and is
confirmed by the decrease of neutrophils count [70].
Although an increased rate of macrolide-resistant organ-
isms was not observed, physicians need to take into consid-
eration the evidence that macrolides resistance is increasing
[72,73]. However, the risk of driving a bacterial resistance
because of long-term macrolide prophylaxis could be
balanced by benefits on the overall bacterial resistance due
to the reduction of number of antibiotic courses. In the trial,
no sputum sample positive for non-tuberculous mycobacterial
infection was identified. Despite that, clinicians have to take
into account that azithromycin could also select resistant non-
tuberculous mycobacteria if mycobacterial infection is present,
especially in presence of bronchiectasis, thus predisposing to
non-tuberculous mycobacterial infection, in the same way as
in CF [74]. As a consequence, pulmonary nontuberculous
mycobacterial infection should be ruled out before starting
long-term azithromycin prophylaxis [74]. On the basis of the
above-mentioned evidence, however, adding azithromycin to
the treatment regimen of PAD patients with chronic infection-
related pulmonary diseases may be considered a good choice.
Apart from antibiotic prophylaxis, physiotherapy represents
another standard adjunct to therapy in NCFB that is used in
PAD patients with bronchiectasis and chronic lung disease,
Figure 1. Bronchiectasis in a CVID patient. Panels show bronchiectasis (arrows) in a CVID patient in two different slices of a chest high-resolution CT scan.
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despite lacking consensus guidelines stating a precise indica-
tion and the best approach [75,76]. A supervised Pulmonary
Rehabilitation and Exercise Training programs might be
recommended to certain patients, even though a short-term
improvement in exercise capacity and Heath-Related QoL,
does not necessarily predict to a long-term benefit [77].
3.1.2.3. Asthma and COPD. Chronic airways inflammation
due to recurrent infections may lead to airway hyper-reactivity
and remodeling, with reversible or fixed obstruction. Indeed, an
impaired antibody response has been suggested as a possible
cause of COPD in those patients without smoking history and/or
alpha-1 proteinase inhibitor deficiency [78]. An association
between bronchial hyper-reactivity aftermethacholine challenge
test and PADs has also been highlighted, particularly when an
IgA deficiency is present [79]. PAD patients also present an
increased frequency of allergic diseases. Thus, frequently exacer-
bating asthmatic and COPD patients are more likely to receive
a diagnosis of PAD, particularly sIgAD, SpAD, IgG subclass defi-
ciency, and CVID [80,81]. This association may account for the
increased frequency of bacterial infections driving acute exacer-
bations of the underlying respiratory disease and for the inade-
quate control despite optimal medical therapy [81,82]. All these
considered, PADs should be ruled out in frequently exacerbating
COPD and severe uncontrolled asthmatic patients, even if some-
times the distinction between primary and secondary antibody
deficiency might be complicated [78,83].
3.1.2.4 Management. The presence of bronchial hyper-
reactivity and fixed obstruction must be ruled out in PAD
patients, performing a complete plethysmography and, when
appropriate, a methacholine challenge. The standard medical
therapy for asthma and COPD may be applied to PAD patients.
Moreover, there is evidence of a positive impact of Ig replace-
ment therapy on chronic obstructive lung diseases, leading to
amelioration of airway obstruction and reduction in the fre-
quency of exacerbations, particularly in asthmatic and
COPD patients with previously undiagnosed PAD [84–86].
Azithromycin prophylaxis and pulmonary rehabilitation pro-
grams may also be helpful. The consequent reduction in courses
and cumulative annual dose of oral corticosteroids, potentially
further lowering the gamma-globulin serum levels, rescue anti-
biotic use, and hospitalizations for acute respiratory exacerba-
tions of asthma and COPDmay have a significant impact on QoL,
development of antibiotic resistance and healthcare costs.
3.2. Immune-mediated lung diseases
Apart from infection-related complication, a great challenge in
PAD patients’ management is currently represented by the
Interstitial Lung Diseases (ILDs). Despite a possible role of
infectious agents as triggers having been hypothesized, the
hallmark of ILDs is represented by immune dysregulation; the
whole pathogenic mechanisms, however, are still far from
being understood [87–90].
3.2.1. Interstitial lung diseases
As for immunocompetent patients, ILDs consist of a group of
diseases relying on a chronic inflammatory and often pro-fibrotic
process clinically characterized by the insidious onset of dry
cough and dyspnoea on effort. Commonly, symptoms do not
occur in the initial stages, and an unrecognized or lately recog-
nized disease progression may lead to pulmonary fibrosis, pos-
sibly complicated by pulmonary hypertension, cor pulmonale,
and progressive respiratory failure. In terms of lung function,
a decrease in carbon monoxide diffusion capacity could precede
the onset of a restrictive pattern at PFTs. Thus, a DLCO reduction
should be investigated by additional dynamic functional testing,
as 6-min walking test (6MWT) or Cardiopulmonary Exercise Test
(CPET). Chest imaging (HRCT) modifications may also anticipate
clinical and functional manifestations [91].
ILDs, rather than recurrent infections and bronchiectasis,
have been suggested as the main cause of a decline in lung
function in patients with CVID [11]. Moreover, the prevalence of
ILDs in PAD patients with recurrent respiratory infections has
been reported as much higher than expected in the general
population [11,92,93]. A prevalence of at least 10–20% has been
reported in CVID, but it is likely underestimated [94,95]. ILDs
have also been reported in other PADs. Occasionally, they may
be found in selective IgA deficiency, particularly when asso-
ciated with IgG subclass deficiency and to a clinical phenotype
dominated by autoimmune features [16]. More commonly, they
have been described as a feature of CTLA-4 haploinsufficiency
and STAT3 gain-of-funtionmutations [96,97]. Granulomatous or
Lymphocytic ILDs have also been described in patients with
a CVID phenotype and an underlying defect in recombination-
activating gene 1 (RAG1), and in lipopolysaccharide responsive
beige-like anchor protein (LRBA) deficiency [98–101]. Finally,
Granulomatous-lymphocytic ILD (GLILD) has been reported in
at least two patients with 22q11.2 deletion syndrome [102]. On
the other hand, there is no evidence of ILDs in different cohorts
of HIGM syndrome and congenital agammaglobulinemia
patients [16]. Thus, the diagnostic process of a primary antibody
deficiency with ILD features should be completed with
a genetic analysis, aimed at identifying defects as LRBA or
CTLA-4 deficiencies that, for instance, belong to the group of
‘diseases of immune dysregulation’ of the IUIS classification of
primary immunodeficiencies. In terms of severity, there are no
data showing specific associations between ILD severity and
the type of PAD.
Different ILD patterns have been described in PADs, includ-
ing follicular bronchiolitis (FB), nodular lymphoid hyperplasia,
sarcoid-like granulomatous disease, organizing pneumonia
(OP), lymphocytic interstitial pneumonia (LIP), non-specific
interstitial pneumonia (NSIP) and hypersensitivity pneumonitis
(HP), with possible radiologic and histologic overlapping fea-
tures [100,103–105]. There is no consistent correlation
between specific ILD patterns and a particular immune defi-
ciency [11]. Systemic immune-mediated disorders potentially
affecting the lung interstitium may also be present in patients
with primary antibody defects (e.g. vasculitis and connective
tissue diseases) [92].
3.2.1.1. GLILD. More recently, the ‘umbrella’ definition of
‘granulomatous lymphocytic interstitial lung disease’ (GLILD)
has been adopted, encompassing granulomatous disease and
all forms of pulmonary lymphoid hyperplasia (PLH) found in PAD
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[95,106]. The exact borders of this definition may appear still not
clear but, due to its broad spectrum of histologic and radiological
patterns, it has been described as the most common ILD in PADs
(Table 2). Thus, we will subsequently refer to GLILD as a spectrum
of diseases rather than to a single, univocal disease.
According to the British Lung Foundation/UK-PID Network
consensus statement, GLILD represents ‘a distinct clinico-radio
-pathological ILD occurring in patients with CVID, associated
with a lymphocytic infiltrate and/or granuloma in the lung,
and in whom other conditions have been considered and,
where possible, excluded’ [108]. GLILD has been associated
with poor clinical outcomes. Its pathogenesis and appropriate
management are currently under investigation [11,18,105].
Infectious agents may act as triggers, as hypothesized for
other granulomatous diseases [90,109]. GLILD is usually
described as part of a multisystem granulomatous/inflamma-
tory disease, potentially involving lymph-nodes, spleen, liver,
GI tract and/or other organs [108,110]. The presence of sple-
nomegaly, past or present immune cytopenias (ITP or AIHA),
low serum IgA levels, higher IgM levels, and percentage
expansion of CD21low B cells have been suggested as highly
sensitive predictors, allowing the identification of a subset of
PAD patients with higher risk for developing GLILD [111,112].
The main histopathological features are represented by
peri-bronchiolar and/or interstitial lymphocytic infiltration
and sarcoid-like non-caseating granulomas. Features of orga-
nizing pneumonia and interstitial fibrosis may also be seen in
a significant proportion of patients. The ectopic B cell follicles
express markers of germinal centers and proliferation despite
the underlying B cell maturation defects [95]. T cells (particu-
larly CD4+) have been described as the predominant lympho-
cyte population in most patients; B cell tissue predominance is
less frequent. Regulatory T cells (Treg) have been reported as
almost absent [100,105].
Despite prognosis having been described as poor, no spe-
cific data are available regarding ILD-related mortality in PAD
patients. It is likely that mortality due to chronic lung disease
in PAD cohorts includes also ILD-related mortality, at least in
those PADs known to be potentially complicated by ILDs
[113]. What we know is mainly derived from CVID-based
studies. In a single-center CVID cohort from Colorado, U.S.,
a significantly worse survival was found between GLILD and
all other non-infectious lung complications [105]. Poorer sur-
vival in CVID has been associated with the prevalence of GLILD
(and cancer) in a recent retrospective analysis of the European
Society for Immunodeficiency (ESID) registry data, while the
presence of granulomatous disease (including extrapulmonary
location) has not been related to a significantly reduced survi-
val in a U.S.-based cohort [10,113].
3.2.1.2 Management. As for other ILDs, patients complaining
dry cough or dyspnea, or showing signatures of ILD during the
routine lung monitoring for PAD, should undergo pulmonary
function tests to rule out the presence of a possible restrictive
pattern, an impairment in gas transfer, hypoxia at rest or on
exercise (during 6MWT or cardio-pulmonary exercise test (CPET)).
High-resolution computed tomography (HRCT), the gold
standard imaging technique for ILDs, may show parenchymal
consolidation, bronchial wall thickening, reticular and/or nod-
ular changes and/or fibrosis, with or without ground-glass opa-
cities, predominantly affecting the lower lobes (Figure 2(a–d)).
Bronchiectasis, air trapping, emphysema may also be present,
since GLILD does not necessarily occur as single lung signature
of PAD [114,115]. No validated radiologic scores are currently
available for GLILD. The differential diagnosis includes infec-
tions, other well-defined ILDs (particularly sarcoidosis) and
monoclonal lymphoproliferative diseases. FDG-positron emis-
sion tomography-CT (PET-CT) may thus be performed when the
initial suspicion is lymphoma, potentially unmasking a clinically
hidden extra-pulmonary involvement. A recent study under-
lined the role of FDG-PET-CT scan also in assessing and mon-
itoring the response to treatment in CVID patients with GLILD
[116] (Figure 2(e)).
Definitive diagnosis, in PAD patients, relies on a high index of
suspicion, on the basis of clinical, radiological and microbiologi-
cal picture, and on histopathologic confirmation [100]. An open
lung or VATS biopsy should be performed, if safe, in order to
provide the Pathologist with an optimal sample. Before surgery,
bronchoscopy is recommended to rule out a possible infectious
explanation for the interstitial picture [108]. The role of Broncho-
Table 2. Main features of GLILD [12,16,107,108,117].
Associated PADs CVID, SIgAD, and IgG subclass deficiency, CTLA-4 haploinsufficiency and STAT3 GOF mutations, RAG1 and LRBA) deficiency. No
evidence in HIGM syndrome and congenital agammaglobulinemia patients [12].
Peripheral B cells Circulating switched-memory B cells may be reduced, while CD21low B cells are often increased [111].
BALF lymphocytes Lymphocytosis is frequent (>20%); CD4/CD8 ratio has been reported increased or normal in different case series. CD21low
B cells have been reported as the major B cell population in BALF [117–119].
Associated lung conditions Frequent infections and possible coexistence of bronchiectasis, COPD and asthma.
Associated extra-pulmonary
conditions
Autoimmune cytopenia and splenomegaly are frequently present, Gastrointestinal involvement is reported in 15% of cases;
there is an increased likelihood of nodular regenerative hyperplasia of the liver [117].
Main non-infectious differential
diagnoses
Sarcoidosis, other ILDs, Malignant lymphoproliferative diseases, metastases or lung cancer
Lung function DLCO reduction, slowly progressing restrictive lung disease [108].
Main radiologic patterns Pulmonary lymphoid hyperplasia features (e.g. LIP, follicular bronchiolitis); NSIP; Organizing Pneumonia. Diffuse lung nodules, often
> 1 cm, with random or predominantly basal distribution; ground-glass opacities; hilar adenopathy may be present [115,117].
Concomitant radiologic findings Bronchiectasis, emphysema, post-infectious aspects
Typical histologic findings Pulmonary lymphoid hyperplasia features, organizing pneumonia, non-necrotizing granulomatous inflammation [100].
Treatment No evidence-based guidelines [108].
Optimize IgG replacement therapy and consider watchful waiting if asymptomatic and no decline in lung function
If treatment is needed:
● Steroids as first line or induction treatment
● Azathioprine/Mycophenolate as steroid-sparing and/or Rituximab
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alveolar lavage fluid (BALF) cytology and flow-cytometric analy-
sis, instead, is not yet defined. BALF has been described as
lymphocyte-enriched (>20%) in adult CVID patients affected by
GLILD. An increased CD4/CD8 ratio of BALF lymphocytes has
been reported, but not confirmed in other case series [117–
119]. CD21low B cells have also been suggested as the dominant
cells in the BALF of patients diagnosed with GLILD [109]. It has
been hypothesized that different BALF lymphocytes distributions
might imply distinct pathogenic mechanisms of GLILD, possibly
deriving from diverse triggers correlating with specific clinical
and prognostic phenotypes [118,119]. Further evidence is
needed to define the exact pathogenic, diagnostic and prognos-
tic role of these lymphocyte sub-populations in GLILD. The role
of trans-bronchial biopsy is not defined, being cryo-biopsy, as for
other ILDS, a more promising approach than EBUS-TBNA
[108,120].
Specific therapeutic guidelines for GLILD are currently lack-
ing. No evidence from controlled trials is available regarding
the appropriate timing for treatment initiation or about spe-
cific therapeutic protocols. The only published data derive
from retrospective studies [109].
The above-mentioned UK consensus statement summarizes
the limited available evidence and recommendations based on
experts’ experience/opinion, together with some open questions
[108]. The first point is to decide whether to treat or not GLILD
once a diagnosis has been made. The choice should be based on
a combination of clinical and functional parameters. There is no
evidence about benefits of treating asymptomatic patients with
normal lung function (not declining over time). Optimization of
the IgG replacement has been suggested, but there is no demon-
stration that increasing the dose of administered IgG has a direct
impact on GLILD progression [121,122]. There is also no evidence
about the use of antimicrobial prophylaxis. However, considering
that GLILD occurs in PAD patients and may be associated with
bronchiectasis, it is likely that maintaining an adequate IgG
trough level may be helpful; for the same reason, the
antimicrobial and anti-inflammatory properties of antibiotic pro-
phylaxis, as previously discussed, may contribute to lower the
degree of lung inflammation.
Symptomatic patients presenting an abnormal or at least
declining lung function might be first-line treated with oral
corticosteroids [108,123]. The decision on whether or how to
treat may also be influenced by concomitant extra-pulmonary
involvement. A general consensus has been reported for the use,
as second-line agents, of azathioprine or mycophenolate, and/or
rituximab (95). Successful treatment of GLILDwith a combination
regimen including rituximab and azathioprine has been recently
reported in a retrospective case series [109]. Few recently pub-
lished case report/series suggested that Rituximabmonotherapy
might also be a reasonable option [115,124,125]. Rationale and
outcome of anti-CD20 treatment in CVID have been recently
discussed in a comprehensive review [126]. The use of other
drugs as hydroxychloroquine, methotrexate, sirolimus, tacroli-
mus, and anti-TNF agents has been described in case reports
[108,127,128]. When an underlying genetic defect is known, e.g.
LRBA deficiency or activated PI3K-δ syndrome, a more targeted
immunomodulator (respectively, abatacept and rapamycin)
might be considered [129,130]
The reported efficacy of immune suppressants suggests that,
despite infectious agents potentially acting as initial triggers,
persistent infection may not substantially contribute to GLILD
progression. The promising results obtained with drugs com-
monly used both in T-cell and B-cell mediated diseases suggest
that both lymphocyte sub-populations may play an active role
in disease progression. It is not clear, however, if different GLILD
phenotypes may be distinguished on the basis of the promi-
nent pathogenic role of either of these two lymphocytes sub-
groups. Rituximab and Azathioprine may improve Treg cells
count [100,131,132]. Moreover, Rituximab has been successfully
used for T-mediated and granulomatous diseases [133].
Recently, a B cell activating factor (BAFF)-driven B cell hyper-
plasia has been shown to be involved in the pathogenesis of
Figure 2. GLILD in CVID patients. Coronal (a) and sagittal (b) view of a CVID patient with a predominantly basal ILD with LIP-like radiological features. Different types
of consolidations in CVID patients (c and d). Panel (d) shows an OP-like radiological pattern. All these patients received histologic diagnosis of GLILD. Panel (e) shows
PET-CT scan of a 45 yo lady presenting GLILD in CVID; FDG uptake highlight mediastinal lymph-nodes, predominantly basal lung consolidations, liver, and spleen,
with significant splenomegaly, bowel, and intraperitoneal lymph-nodes.
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ILD in CVID [125]. This further strengthens the rationale of anti-
CD20 therapy, opening the way also to anti-BAFF therapy.
Whether a tailored choice of the most appropriate treatment
might be extrapolated by the histologic pattern or by any
disease biomarker (e.g peripheral blood or BALF-derived med-
iators or lymphocyte distribution) is still an open question.
3.3. Neoplastic diseases involving the lung
Cancer is a relevant cause of morbidity and mortality in Primary
Antibody Deficiencies. Lymphoma and gastric carcinoma are the
most represented neoplastic diseases [6,13,56]. Primary lym-
phoid lesions may affect the lung of PAD patients, including non-
Hodgkin lymphomas, as low-grade B-cell lymphoma of mucosa-
associated lymphoid tissue (MALT), and Hodgkin disease
[134,135]. Of note, the diagnosis of Epstein-Barr Virus (EBV)-
driven lymphoproliferative diseases in patients with hypogam-
maglobulinemia and history of recurrent bacterial infections
should raise the suspicion of a CD27-CD70 axis deficiency [136].
In this case, diagnosis relies on genetic analysis moving the
investigated PID from the ‘predominantly antibody deficiencies’
to the ‘diseases of Immune dysregulation with Hemophagocytic
Lymphohistiocytosis and EBV susceptibility’ group of the IUIS clas-
sification [1]. Neoplastic lymphoproliferative diseases should be
considered in the differential diagnosis of GLILD [137]. Different
case series reported also lung carcinoma in CVID patients, but
lung infiltration with metastases of other cancers appears to be
more common than primary lung tumors [56,92,135]. Even if an
increased prevalence of malignant lymphoma and of gastric
cancer has been observed in an Italian cohort of 455 CVID
patients, the prevalence of lung cancer in that cohort was 0.9%,
lower than that reported in general population, with
a significantly lower mortality if compared to normative Italian
population [13]. A Thymic enlargement/mass at chest CT scan in
a patients with hypogammaglobulinemia, finally, should raise
the suspicion of a Thymoma-associated Good’s Syndrome [138].
4. Conclusions
Lung disease is a common and relevant clinical feature of
Primary Antibody Deficiency. The availability of different
options of IgG replacement therapy, allowing treatment per-
sonalization, has significantly reduced the recurrence of infec-
tions, particularly in early diagnosed patients. However,
diagnostic delay still represents a great concern, particularly
for PAD presenting in the adulthood, and once the lung
damage is established, the risk of colonization and further
infections increases [10]. Moreover, IgG replacement does
not fulfill all the patients’ requirements, and the persistence
of IgA and IgM deficiency and other concomitant immune
defects have extensively been highlighted as risk factors for
the progression of lung disease [31]. Apart from replacement
therapy, no specific and evidence-based guidelines for diag-
nostic and therapeutic management of lung diseases in PADs
are currently available [14]. The most relevant new data, in the
field, are those recently published about antibiotic prophylaxis
with azithromycin [70]. The management of bronchiectasis,
asthma, and COPD might be somehow borrowed from the
same conditions occurring in non-PAD patients, provided that
the PAD condition had been diagnosed and Ig replacement
therapy had been established. Nonetheless, further specific
evidence is needed in cohorts of PAD patients. On the con-
trary, the management of ILD is much more challenging. Too
little is known about pathogenesis, and about correlations
between histology, radiology, serum markers, and disease
behavior. Moreover, the need for a tailored treatment which
could maximize the effect on lung disease while minimizing
the immune suppressive power, particularly when acting
broader than on B-cell mediated immunity, is definitely higher
in PAD than in immune competent patients [139]. Immune-
mediated diseases, indeed, do not necessarily occur separately
from chronic infection-related lung disease.
Thus, future studies are needed, as well as a broader
degree of awareness of epidemiologic and etiologic relation-
ships between PADs and specific pulmonary manifestations.
A better understanding of the specific mechanisms leading
from immunodeficiency to immune dysregulation, particularly
when an underlying monogenic defect cannot be demon-
strated, will open the way to more personalized diagnostic
and therapeutic approaches. The reduction of diagnostic delay
and a better understanding of lung diseases mechanisms and
consequent therapeutic options will have a strong impact on
Quality of Life and long-term prognosis of PAD patients.
5. Expert opinion
5.1. Practical approach to lung disease in PADs
Lacking internationally recognized guidelines about screening
and management of lung diseases in PAD patients, different
approaches are ongoing in distinct Countries and, sometimes,
even in different referral centers within the same Country [14].
What we currently recommend in Italy is to adopt
a standardized approach at diagnosis and a personalized
approach during follow-up, keeping in mind the above-
mentioned possible pulmonary complications and their pre-
clinical and clinical signs [140]. The initial work-up of
a possible lung disease in PAD includes high-resolution chest
CT scan and Pulmonary function tests encompassing spirome-
try (with eventual post-bronchodilator test or methacholine
challenge), gas transfer measurement and blood gas analysis
[12]. It is indeed important to establish whether patients pre-
sent or not bronchiectasis, lymph-node enlargement, radiolo-
gical signs of ILDs, as well as an obstructive, restrictive or
combined respiratory disorder, possibly associated with an
impairment in gas transfer or blood oxygenation. As discussed
above, this initial assessment allows clinicians to optimize Ig
replacement therapy and all the possible add-ons, including
antibiotic prophylaxis and inhalation therapy. At the time of
the initial assessment, a lung MRI may be considered as
a complementary investigation. Lung MRI is performed in
contexts where recurrent lung imaging may be required, as
a radiation-sparing techniques, e.g. in cystic fibrosis; radiolo-
gists may thus be used to evaluate signatures of chronic lung
disease, including bronchiectasis. The reliability of lung MRI in
PAD patients has already been demonstrated in previous stu-
dies, and its use in routine monitoring will likely increase in
the next future [141,142]. This radiation-sparing technique has
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indeed a great potential for application in PAD patients, which
are often young and more prone to cancer than the general
population.
The initial work-up has to include a genetic screening for the
well-known mutations associated to PAD phenotypes and related
lung involvement, together with all the investigations possibly
highlighting risk factors for specific lung disease patterns (we
already discussed the putative risk factors for GLILD, e.g. spleno-
megaly and percentage expansion of CD21low B cells).
Ig replacement therapy has to be established at the dosage
of 400–800 mg/kg every 4 weeks, adjusting the initial dose
according to the frequency of infections and IgG trough levels.
The route and the schedule of administration and the optimal
replacement dosage have to be individualized [143]. No specific
difference between intravenous (IVIg) and subcutaneous (SCIg)
administration of Ig has been clearly demonstrated, in terms of
impact on PAD-related lung complications, despite a lower
degree of bronchiectasis under SCIg treatment having been
described in certain cohorts of patients [76]. The main goal is
to obtain and keep stable the optimal IgG trough level for each
single patient, independent on route of Ig administration.
According to recent evidence, apart from Ig replacement ther-
apy, in patients presenting bronchiectasis or COPD, we recom-
mend to establish an antibiotic prophylaxis with azithromycin,
if not contraindicated. A supervised Pulmonary Rehabilitation
and Exercise Training programs should be recommended to
patients suffering from bronchiectasis and/or COPD complain-
ing frequent acute exacerbations.
In case of suspicion of ILD raising from the initial work-up,
6-MWT and/or a CPET test should be promptly performed.
According to the results of functional assessment and to the
presence or absence of symptoms, patients might be then
recommended either a therapeutic approach or a watchful wait-
ing strategy. In this second circumstance, not only a functional
but also a radiologic close monitoring is needed. Thus, despite
HRCT being the current gold standard imaging technique, the
importance of Lung MRI is destined to increase [144,145].
Once a clinical and radiologic suspicion of GLILD has been
formulated, a bronchoalveolar lavage is recommended to rule
out an infection as cause of the interstitial lung disease. The role
of BALF lymphocyte flow-cytometric analysis in the diagnostic
process is not yet defined. Nonetheless, preliminary data sug-
gested a possible relationship between the lymphocyte subpo-
pulations distribution and the clinical behavior of GLILD
[117–119]. BALF lymphocytes may be helpful in the diagnostic
work-up of ILDs, including sarcoidosis. In this last case, in spe-
cific circumstances, a definite diagnosis of sarcoidosis may rely
on the combination between a suggestive clinical-radiologic
picture and a CD4/CD8 ratio [90]. Moreover, an increase in
B cells may allow to assess a possible clonal restriction of sur-
face Ig light chains and, in case malignancies had been ruled
out, might suggest a more B-cell targeted approach with anti-
CD20 treatment. Positron emission tomography with Fluoro-
D-glucose (FDG-PET) combined with CT scan (or with MRI, when
available) represents a reasonable option in the work-up, com-
bining a well-established role in the differential diagnosis of
lymphoproliferative disease and a recently described value in
initial work-up and in response-to-treatment evaluation of
GLILD. Finally, to confirm a diagnosis of GLILD versus the suspi-
cion of lymphoma, a histologic examination is required.
Transbronchial biopsy generally offers small samples, that
may be inadequate to observe the typical histologic heteroge-
neity of GLILD and to exclude a malignant lymphoproliferative
disease. Thus, an open-lung or VATS biopsy is currently recom-
mended as above described. However, in the field of ILDs,
transbronchial cryo-biopsy has been gaining importance over
the last few years, offering more adequate samples while spar-
ing the higher risks potentially related to surgery [108,120]. At
present, in light of the just mentioned risks and of the lack of
evidence about any specific treatment of GLILD, in absence of
symptoms and without signs of functional decline, the oppor-
tunity of an invasive approach should be carefully evaluated by
clinicians and discussed with patients. In our opinion, in these
circumstances and once ruled out infections and lymphomas (a
lymph-node transbronchial biopsy might be enough in many
cases and a bronchoalveolar lavage might offer much informa-
tion), a watchful waiting might be more cost-effective than an
immediate surgical lung biopsy. Thus, we suggest establishing
a close monitoring schedule, with the evaluation of lung func-
tion after 3 months and, later, every 6 months. Chest CT scan
should be repeated after 6 months and, subsequently, once
a year or according to specific requirements. Once more, lung
MRI is destined to become a cornerstone of the watchful wait-
ing strategy. However, at the first evidence of disease progres-
sion, surgical lung biopsy is still recommended, provided that
we still do not know how a specific histologic or histochemical
pattern of GLILD may influence our therapeutic strategy.
Regarding GLILD treatment, first of all, we recommend
treating symptomatic patients and those presenting a clear
decline in lung function. Treatment of asymptomatic patients
without decline in lung function might only be considered in
those patients with radiologic evidence of disease progression
and a specific underlying genetic defect (e.g. LRBA deficiency),
where disease biology may at present be better predicted and
targeted. The increase in serum IgM levels has also been
suggested as a marker of more severe disease behavior that
should be taken into account [125]. Optimization of Ig repla-
cement therapy is reasonable, both for preventing acute
respiratory exacerbations and for down-modulating any pos-
sible infection-related inflammatory trigger. The first-line ster-
oid treatment is a standard approach in inflammatory ILDs and
may be considered in the presence of an Organizing
Pneumonia predominant pattern. In most of other cases and
particularly when granulomatous inflammation is detected, in
the absence of therapeutic guidelines, we take some hints
from our experience in the treatment of chronic sarcoidosis.
Since a long-term treatment is generally needed, the use of
steroids alone is generally burdened by many side effects even
in immunocompetent patients. Thus, we prefer to use corti-
costeroids as induction treatment while starting an immuno-
suppressant as Azathioprine or Mycophenolate to be
continued as long-term treatment. However, when a rapid
clinical response is needed, our first choice tends to be the
anti-CD20 treatment with Rituximab, that has been shown
effective in different ILD contexts, including selected cases of
sarcoidosis and GLILD [125,133].
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In terms of routine follow-up, finally, lung function (parti-
cularly FEV1 and DLCO) is known to decline slowly over time
in patients with PID, despite appropriate replacement therapy
[67]. Thus, annual testing with spirometry and CO transfer
measurement is recommended in PAD patients, with or with-
out functional or radiologic evidence of chronic lung disease.
As already discussed, DLCO reduction may be an early signal
of an ongoing, clinically not evident, interstitial lung disease,
even in the absence of a restrictive pattern at PFTs. HRCT scan
can be even more sensitive, showing interstitial modifications
before any impairment in gas transfer. However, due to the
exposure to ionizing radiations, CT scan is generally recom-
mended to be performed once every 5 years in the absence of
specific clinical indications. The increasing performances of
chest MRI will hopefully allow clinicians to prescribe more
frequent imaging assessments, particularly in selected patients
with known risk factors for ILD. This will also be helpful in
those patients with a diagnosis of GLILD without immediate
indication to treatment. Figure 3 recapitulates the step-by-
step approach to lung monitoring in PADs.
Starting from recent evidence and open questions already
discussed in this review, in the next 3–5 years we expect to
have some major advances that will significantly modify (and
standardize) the management of lung disease in PAD:
(1) In PAD patients, IgG replacement therapy has been
shown to enhance survival and reduce severe and inva-
sive infections. However, patients might still develop
chronic infection-related lung disease (CLD). Recurrent
respiratory tract infections are indeed linked to low
serum IgA levels, reflecting a severely impaired isotype
switching process leading to a loss of function of memory
B cells. It has been recently suggested that there have
been limited innovations over the last 65 years in Ig
Figure 3. Monitoring and management of lung disease in primary antibody deficiencies.
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replacement therapy. Despite having improved the ther-
apeutic options in terms of route and schedule of admin-
istration and tolerability of the different preparations,
indeed, we are still not able to provide IgA or IgM replace-
ment [146]. IgA and IgM enriched preparations are cur-
rently under evaluation, being the lack of the secretory
domain the main limitations, at present. Recently, recom-
binant secretory component to be combined with
plasma-derived IgA and IgM have been tested in animal
studies with promising results. Human plasma-derived
polyreactive IgA and IgM antibodies reconstituted as
secretory-like immunoglobulins have been shown to be
effective when used for oral passive immunization in
murine models of experimental salmonellosis [147].
Nebulized inhaled Ig (IgA/IgM), will also be available in
the near future [148]. These new preparations might be
useful to prevent the progression of CLD and will offer
a therapeutic option for SIgAD and selective IgM defi-
ciency patients. The potential limitation might be repre-
sented by the development of anti-IgA IgG (and possibly
IgM) antibodies, potentially inducing anaphylactoid reac-
tions to IgA-containing preparations [149,150]. However,
the risk will be limited to those patients with absolute IgA
deficiency (undetectable IgA) and still able to produce
specific IgG (or IgM); the subcutaneous route of adminis-
tration has been shown to be safer, in these patients [149].
(2) As suggested above, recent evidence supports the pos-
sible role of lung magnetic resonance imaging (MRI) in
diagnosing and monitoring chronic lung disease in PAD
patients. On the other hand, in ILDs the potential of MRI
is much more uncertain. Accordingly, future multi-
centric studies will be needed due to the lower number
of PAD patients presenting GLILD if compared to
bronchiectasis. However, thin-slices chest CT scan can-
not distinguish pure inflammatory from fibrotic ground-
glass opacity. On the contrary, recently developed chest
MRI techniques, while not adding information to HRCT
scan in terms of image quality, may provide in ILDs
both structural and functional information in a single
examination. They can indeed add information about
inflammation, ventilation, and perfusion, being poten-
tially helpful in assessing ILD progression and in pre-
dicting its response to treatment [144,145]. All these
considered, without exposure to ionizing radiation,
chest MRI will offer also in PAD-associated ILDs better
tissue characterization, differentiating between inflam-
matory and purely fibrotic ground-glass opacities [144].
Recent and near-future advances will thus hopefully
lead to the routine use of lung MRI at diagnosis, in
a combined approach together with HRCT, and as
gold standard for the 3–5 years follow-up in PAD
patients, being HRCT used only on demand.
(3) The recent controlled trial on Azithromycin prophylaxis
will be helpful in designing a more standardized
approach to CLD in PAD patients. However, further
multicenter-controlled trials are needed, in order to
define PAD-specific evidence-based guidelines for the
management of infection-related lung diseases.
(4) The diagnosis of GLILD is currently based on a multi-step
process culminating in an invasive open-lung or VATS
biopsy. The increasing awareness of this lung complica-
tion will hopefully lead to earlier suspicion and to more
limited risks eventually related to a surgical biopsy.
However, the world of ILDs is moving towards clinical-
radiologic diagnoses based on the exclusion of causes of
secondary lung diseases and on a Multi-Disciplinary
Team (MDT) discussion. Thus, the diagnosis of GLILD is
also destined to move to a more clinical-radiological-
plus -MDT -discussion-based approach. VATS and open-
lung biopsy will then be limited to those cases when
other lung diseases cannot be ruled out in a different
way (e.g. transbronchial biopsy or biopsy of a different
tissue in the context of a systemic disease). Cryo-biopsy
will likely become the first-line approach when a lung
tissue biopsy is needed.
(5) The treatment of GLILD definitely represents the major
concern. Observational studies are ongoing but, due to
the rarity and heterogeneity of this condition, we are
still far from multicenter interventional-controlled stu-
dies possibly leading to evidence-based guidelines.
Thus, the next advances will still derive from case series
and retrospective/prospective observational studies.
Nonetheless, these studied will start providing interest-
ing correlations between possible predisposing factors,
concomitant conditions, peripheral blood or BALF lym-
phocytes distribution (e.g. CD4/CD8 ratio, CD21lo
B cells or large granular lymphocytes expansion), histo-
chemical characterization of tissue samples and GLILD
behavior. The recent paper published by Maglione et al.
represents an appropriate paradigm of this kind of
studies [125]. Response to treatment will also be put
in relation to all the above and to possible underlying
genetic defects sustaining a peculiar pathogenic path-
way. This will allow clinicians either to classify patients
in different subgroups in terms of prognosis and pre-
dicted response to specific treatment, or to take into
account all the possible immunologic mechanisms or
biomarkers of each single patients in order to design
a tailored treatment strategy.
(6) Starting from these data that will hopefully be pub-
lished in the next 3–5 years, it will be possible to design
relatively large multicenter-controlled trial with existing
drugs that will be the basis for PAD-specific evidence-
based treatment guidelines for ILDs.
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